Pregnanolone

Pregnanolone is an endogenous inhibitory neurosteroid belonging to the pregnane family of steroids. Chemically it is 3-alpha-hydroxy-5-beta-pregnan-20-one, also written as 3-alpha,5-beta-tetrahydroprogesterone, and it is produced from progesterone through the enzymes 5-beta-reductase and 3-alpha-hydroxysteroid dehydrogenase ^[1]. It is one of several progesterone-derived neuroactive steroids, closely related to allopregnanolone.

As a group, these neurosteroids act as rapid modulators of nerve-cell excitability, and their levels rise and fall with the menstrual cycle, with stress and during pregnancy ^[1]. Pregnanolone, alongside allopregnanolone, is thought to contribute to the sedated, quiescent state of the fetus before birth. Reviews of neuroactive steroid pharmacology place pregnanolone among the potent positive modulators of the GABA-A receptor, the class responsible for sedative, anti-anxiety and anticonvulsant effects ^[1].

The main clinical exploration of pregnanolone was as an intravenous general anaesthetic under the international name eltanolone. Human pharmacokinetic and pharmacodynamic studies in the 1990s showed that it induced and ended anaesthesia quickly and had a favourable pharmacokinetic profile ^[2], and a lipid-emulsion formulation was reported to give smooth, reliable induction of anaesthesia ^[3]. Despite these promising features it was never brought to market, partly because of occasional adverse effects. Interest in the wider class has nonetheless continued: a closely related neurosteroid, allopregnanolone, was later developed into the approved drug brexanolone for postpartum depression ^[4].

Pregnanolone is not itself a marketed medicine. It exists naturally in the body, and outside of that it has been handled only as an experimental intravenous agent in research settings rather than as an approved therapeutic product.

In its clinical incarnation as the intravenous anaesthetic eltanolone, pregnanolone produced smooth induction with little or no pain on injection and notably less cardiovascular and respiratory depression than propofol; uniquely among general anaesthetics it did not trigger malignant hyperthermia (a life-threatening anaesthetic reaction of skeletal muscle) in genetically susceptible swine, and it even attenuated halothane-induced episodes. The main liabilities recorded in 1990s trials were slower emergence and recovery than propofol and transient cutaneous flushing or rash consistent with histamine release, the latter having been the downfall of the earlier Cremophor-solubilised steroid anaesthetics.

Excitatory phenomena such as involuntary movements and, rarely, convulsions were reported historically with steroid anaesthesia. As an endogenous molecule pregnanolone is generally well tolerated at physiological levels, but strong GABA-A potentiation carries dose-related sedation, motor incoordination and impairment of spatial memory, and in individuals sensitive to GABA-A active steroids it can paradoxically worsen mood, as observed with related pregnane steroids in premenstrual dysphoric disorder. It is not sold as a dietary supplement and is not orally active, and no modern human safety dataset exists beyond the discontinued anaesthetic programme.

Pregnanolone (eltanolone) is a 3-alpha,5-beta neurosteroid that acts as a positive allosteric modulator of the GABA-A receptor, and its documented concern is additive central nervous system and respiratory depression when combined with other GABAergic or CNS depressant agents. During its development as an intravenous anesthetic, dose requirements for co-administered anesthetics and sedatives were reduced, reflecting pharmacodynamic additivity. By the same GABA-A mechanism, the closely related neurosteroid allopregnanolone (brexanolone) carries a labeled warning for excessive sedation and loss of consciousness when given with benzodiazepines, opioids, alcohol, or other CNS depressants. There are otherwise no well-characterized cytochrome P450 interaction studies for pregnanolone itself. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Pregnanolone sits within a long lineage of steroid anaesthesia. Interest began after Hans Selye reported in 1941 that certain pregnane steroids were rapidly anaesthetic; the water-soluble ester hydroxydione followed in the 1950s but was hampered by slow onset and thrombophlebitis. In 1972 the mixture of alphaxalone and alphadolone (Althesin) reached wide clinical use, only to be withdrawn in 1984 after anaphylactoid reactions traced to its solubiliser, polyethoxylated castor oil (Cremophor EL). Pregnanolone itself had been isolated from the urine of pregnant women in 1937, with anaesthetic activity recognised by mid-century.

To avoid Cremophor, Kabi Pharmacia of Stockholm formulated pregnanolone as a stable soybean-oil-in-water emulsion, and under the name eltanolone it advanced through Phase I to Phase III testing in the early to middle 1990s, including volunteer pharmacokinetic and electroencephalographic studies, paediatric induction, and positron emission tomography of cerebral blood flow.

Development was nonetheless discontinued because recovery was slower than with propofol and skin reactions persisted. The neurosteroid field was subsequently revived by allopregnanolone (marketed as brexanolone for postpartum depression) and the synthetic analogue ganaxolone, while a Prague based group at the Czech Academy of Sciences pursued pregnanolone esters as use-dependent NMDA antagonists for neuroprotection.

Within neuropharmacology pregnanolone is a canonical positive allosteric modulator of GABA-A receptors and, as eltanolone, a much-cited example of a promising intravenous anaesthetic that failed at the recovery hurdle rather than on safety. It is perennially the lesser known of the two natural tetrahydroprogesterones, overshadowed by its 5α epimer allopregnanolone, which became the first approved neurosteroid drug (brexanolone).

In nootropic and biohacking communities pregnanolone has essentially no presence as a consumable, because it is not orally active and is not marketed; its name surfaces mainly in technical discussions of neurosteroid mood regulation, of stereochemistry (its 3β and 5α relatives having opposite or distinct actions), and in contemporary medicinal chemistry aimed at use-dependent NMDA blockers. Among specialists it is valued both as a pharmacological reference compound and as a cautionary case study in anaesthetic formulation and pharmacokinetics.